Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
1999-10-05
2002-05-14
Azpuru, Carlos A. (Department: 2165)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S434000, C424S435000, C424S451000, C424S464000
Reexamination Certificate
active
06387390
ABSTRACT:
BACKGROUND OF THE INVENTION
The compositions and methods of use described herein generally are in the field of materials and methods for enhancing cellular internalization.
It is often difficult to deliver compounds, such as proteins, peptides, genetic material, and other drugs and diagnostic compounds intracellularly because cell membranes often resist the passage of these compounds. Various methods have been developed to administer agents intracellularly. For example, genetic material has been administered into cells in vivo, in vitro, and ex vivo using viral vectors, DNA/lipid complexes, and liposomes. While viral vectors are efficient, questions remain regarding the safety of a live vector and the development of an immune response following repeated administration. Lipid complexes and liposomes appear less effective at transfecting DNA into the nucleus of the cell and potentially may be destroyed by macrophages in vivo.
Proteins and peptides are typically administered by parenteral administration, or, in some cases, across the nasal mucous membrane. Uptake of drugs administered topically is frequently poor, and degradation frequently occurs when drugs are administered orally. For example, hormones such as gonadotropin releasing hormone (“GnRH”) and its analogs have been administered to humans in an attempt to increase fertility by increasing systemic levels of luteinizing hormone (“LH”). When given often, low doses of native GnRH have been shown to induce follicular development and ovulation. These drugs are typically administered via an indwelling catheter into the abdominal cavity. An external pump is attached to the catheter which injects the peptide at frequent intervals. This method of administration is extremely invasive and undesirable. Also, the method is prohibitively expensive for use in animals.
It has recently been demonstrated that, by embedding individual cell populations in hydrogel media of macroscopic viscosity similar to that characteristic of cell cytoskeleta, the rate of receptor-mediated endocytosis can be significantly enhanced (Edwards, et al.,
Proc. Natl. Acad. Sci. U.S.A
. 93:1786-91 (1996); PCT US97/03276 by Massachusetts Institute of Technology and Pennsylvania State University Foundation). This enhancement effect appears to reflect a fluid-mechanical origin of receptor-mediated endocytosis, involving the rapid expansion of plasma membrane in the vicinity of a receptor cluster leading to an invaginating membrane motion that is sensitive to the viscous properties of the extracellular environment (Edwards, et al.,
Proc. Natl. Acad. Sci. U.S.A
. 93:1786-91 (1996); Edwards, et al.,
Biophys. J
. 71:1208-14 (1996)).
It has been found, however, that the delivery of compounds via a receptor-mediated route into the systemic circulation by noninvasively delivering the compound in a “rheologically-optimized” hydrogel may be inconsistent or poorly reproducible. It would be advantageous to better understand the role of RME in uptake of compounds in order to develop improved methods of delivery of compounds, such as drugs, intracellularly.
The binding of ligands or assembly proteins to surface receptors of eucaryotic cell membranes has been extensively studied in an effort to develop better ways to promote or enhance cellular uptake. For example, binding of ligands or proteins has been reported to initiate or accompany a cascade of nonequilibrium phenomena culminating in the cellular invagination of membrane complexes within clathrin-coated vesicles (Goldstein, et al.,
Ann. Rev. Cell Biol
. 1:1-39 (1985); Rodman, et al.,
Curr. Op. Cell Biol
. 2:664-72 (1990); Trowbridge,
Curr. Op. Cell Biol
. 3:634-41 (1991); Smythe, et al.,
J. Cell Biol
. 108:843-53 (1989); Smythe, et al.,
J. Cell Biol
. 119:1163-71 (1992); and Schmid,
Curr. Op. Cell Biol
. 5:621-27 (1993)). This process has been referred to as receptor-mediated endocytosis (“RME”). Beyond playing a central role in cellular lipid trafficking (Pagano,
Curr. Op. Cell Biol
. 2:652-63 (1990)), RME is the primary means by which macromolecules enter eucaryotic cells.
An effective strategy for enhancing the uptake of cytotoxic and therapeutic drugs involves exploiting the rapidity and specificity of transmembrane transport via receptor-mediated endocytosis (Goldstein, et al.,
Ann. Rev. Cell Biol
. 1:1-39 (1985)) by targeting receptors on the plasma membranes of endothelial (Barzu, et al.,
Biochem. J
. 15;238(3):847-854 (1986); Magnusson & Berg,
Biochem. J
. 257:65-56 (1989)), phagocytic (Wright & Detmers, “Receptor-mediated phagocytosis” in
The Lung: Scientific Foundations
(Crystal, et al., eds.), pp. 539-49 (Ravens Press, Ltd., New York, N.Y.(1991)); and tumor cells, as well as cells of other tissues. Receptor targeting has, however, not been championed as a means of avoiding intravenous injection of hard-to-absorb macromolecules, probably because macromolecules often degrade prior to reaching receptors in the gastrointestinal tract following oral administration, and do not appear to require receptor-mediation to permeate across the alveolar epithelium following inhalation. Other noninvasive macromolecular drug delivery strategies either do not expose receptors to the topical environment, for example transdermal delivery, or have been less extensively explored, such as nasal delivery (Illum, et al.,
Int. J. Pharm
. 39:189-99 (1987)), vaginal delivery, or ocular delivery.
It is therefore an object of the present invention to provide compositions and methods for enhancing intracellular delivery of bioactive and/or diagnostic agents, especially steroidal compounds and materials which are endocytosed by a receptor-mediated mechanism.
SUMMARY OF THE INVENTION
Compositions and methods for improving cellular internalization of one or more compounds using a receptor mediated mechanism are disclosed. The compositions include a compound to be delivered and a biocompatible viscous material, such as a hydrogel, lipogel, or highly viscous sol, and are administered subsequent to or with steroid or other material binding to the receptor at the site of application to enhance uptake (referred to as an “enhancer”). By controlling the apparent viscosity of the viscous materials, the rates of endocytosis, including nonspecific “pinocytosis” and specific RME, are increased. The rate of endocytic internalization is increased when the ratio of the apparent viscosities of cytosolic and extracellular media approaches unity. The composition includes, or is co-administered with, the enhancer, usually a steroid or other molecule binding to receptors at the site of application in an amount effective to maximize binding to the receptors or expression of receptors and enhance RME of the compound into the cells. This leads to high transport rates of compounds to be delivered across cell membranes, facilitating more efficient delivery of drugs and diagnostic agents.
Preferred viscous materials are hydrogels, lipogels (gels with nonaqucous fluid interstices) and highly viscous sols. The apparent viscosity of the composition is controlled such that it lies in the range of between 0.1 and 2000 Poise, preferably between 7 and 1000 Poise, and most preferably between 2 and 200 Poise. Compounds to be delivered include those that can be attached, covalently or noncovalently, to a molecule that either stimulates RME or pinocytosis by binding to receptors on the plasma membrane, binds specifically to receptors that undergo RME or pinocytosis independently of this binding (i.e., which are themselves “enhancers”) or at least can be associated chemically or physically with other molecules or “carriers” that themselves undergo RME or pinocytosis. Exemplary compounds to be delivered include proteins and peptides, nucleotide molecules, saccharides and polysaccharides, synthetic chemotherapeutic agents, and diagnostic compounds. The examples demonstrate the roles of estrogen and progesterone in vaginal delivery of peptide hormones. Peptide transport into the systemic circulation is strongly steroid-dependent, with most efficient transport of repro
Deaver Daniel R.
Edwards David A.
Azpuru Carlos A.
Holland & Knight LLP
The Penn State Research Foundation
LandOfFree
Compositions and methods for enhancing receptor-mediated... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for enhancing receptor-mediated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for enhancing receptor-mediated... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2870287